Pancreatic cancer is an extremely aggressive disease with a 90% five-year mortality rate and limited effective treatments. Standard therapies like gemcitabine often fail to improve outcomes significantly, and the disease is frequently diagnosed at a late, metastatic stage when treatment options are most limited.
Plumbagin is a natural compound isolated from the plant Plumbago zeylanica, used in traditional Chinese medicine. Laboratory studies have shown it has anti-cancer and anti-proliferative properties in several cancer types, including breast, liver, and lung cancer. However, its specific effects on pancreatic cancer and the molecular mechanisms involved have not been well characterized.
Rather than running laboratory experiments, the researchers used network pharmacology — a computational approach that maps out the interactions between a drug and its potential biological targets in the context of a specific disease. Candidate targets for plumbagin were identified from multiple drug-target prediction databases (SwissTargetPrediction, PharmMapper, DrugBank, SuperPred).
Pancreatic cancer-associated genes were retrieved from the DisGeNET database. The overlap between plumbagin targets and pancreatic cancer genes was identified, and protein-protein interaction (PPI) networks were built using the STRING database (interactions with confidence score >0.9). Cytoscape was used to visualize network hubs — the most highly connected and influential targets.
KEGG pathway analysis and Gene Ontology (GO) analysis were performed to understand the biological processes, molecular functions, and signaling pathways through which plumbagin might act on pancreatic cancer cells.
The analysis identified four key 'hub' targets for plumbagin in pancreatic cancer: TP53 (a master tumor suppressor gene), MAPK1 (a cell signaling kinase), BCL2 (a protein that prevents cancer cell death), and IL6 (an inflammatory cytokine). These are among the most important genes in cancer biology and known drivers of pancreatic cancer progression.
A total of 1,731 biological annotations and 121 enriched signaling pathways were identified. The top 10 pathways included cancer signaling, apoptosis (programmed cell death), the PI3K-Akt pathway, the MAPK pathway, and pathways related to inflammation — all of which are critical in pancreatic cancer biology.
The identification of TP53, BCL2, and IL6 as top targets is significant. TP53 is mutated in the majority of pancreatic cancers and governs programmed cell death; compounds that restore its function or interact with its pathway could inhibit tumor growth. BCL2 is frequently overexpressed in cancers and promotes cancer cell survival by blocking apoptosis — a target that many anti-cancer drugs aim at.
IL6 is a major inflammatory mediator that promotes tumor growth and immune evasion in pancreatic cancer. Plumbagin's predicted action on this target suggests it may have anti-inflammatory effects within the tumor microenvironment, which could complement other treatment strategies.
This network pharmacology study provides a computational blueprint for how plumbagin may act against pancreatic cancer. The identified targets and pathways give researchers a prioritized set of experiments to validate in laboratory and animal models.
The authors emphasize that these are predictions based on computational models and require experimental confirmation. If validated, plumbagin could represent a promising natural compound for development as a pancreatic cancer therapeutic, either alone or in combination with existing treatments.